Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,619 across all filing types
Latest filing 2025-02-03 Investor Presentation
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Investor Presentation Euroz Hartleys Healthcare Forum 22 pages 1.8MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation from a healthcare forum dated February 2025, featuring the CEO and focusing on clinical trial updates, investment highlights, scientific data, and company strategy. It includes forward-looking statements, clinical trial interim results, shareholder information, and detailed scientific and clinical data about the company's drug development pipeline. The content is typical of an investor presentation aimed at providing comprehensive information on the company's financial position, clinical progress, and market opportunity. There is no indication that this is a formal regulatory filing like an annual or interim report, audit report, or earnings release. It is not a transcript of a call, nor a voting or board management announcement. The length and detail, combined with the focus on investment highlights and clinical data, strongly indicate this is an Investor Presentation (IP).
2025-02-03 English
Quarterly Appendix 4C Cash Flow Report 5 pages 757.7KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B' and contains detailed quarterly cash flow statements including operating, investing, and financing activities. It includes financial data for the quarter ended 31 December 2024 and year-to-date figures, as well as compliance statements and notes referencing ASX Listing Rules. The document is approximately 10,782 characters long, which is substantial and contains actual financial data, not just an announcement or certification. This matches the characteristics of an Interim / Quarterly Report (IR) as it provides comprehensive financial information for a period shorter than a full fiscal year. Therefore, the correct classification is IR.
2025-01-28 English
Quarterly Shareholder Report 5 pages 239.7KB
Interim / Quarterly Report Classification · 100% confidence The document is a quarterly shareholder report dated 29 January 2025, summarizing activities and financial performance for the quarter ended 31 December 2024. It includes detailed interim clinical trial results, capital raising information, financial performance data including cash balances and R&D tax incentives, and payments to related parties. The document is comprehensive and contains substantive financial data and analysis for a period shorter than a full fiscal year (quarterly). It is not merely an announcement or a brief summary but a detailed report with financial and operational updates. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2025-01-28 English
Application for quotation of securities - SNT 6 pages 18.8KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) announcement for the application for quotation of securities. It details the issuance and quotation of new securities resulting from the exercise of options or conversion of convertible securities. The document includes specifics such as the number of securities, issue date, and whether the securities are part of an employee incentive scheme. This type of filing is related to changes in the company's capital structure, specifically the issuance and quotation of new shares. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document is not a report or announcement of financial results, nor is it a regulatory announcement unrelated to capital changes. Hence, the correct classification is SHA with high confidence.
2025-01-21 English
Notice of General Meeting/Proxy Form 21 pages 486.6KB
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled 'NOTICE OF GENERAL MEETING AND EXPLANATORY STATEMENT' and details the arrangements for a general meeting of shareholders, including the date, time, virtual meeting instructions, and the resolutions to be voted on. It includes proxy voting instructions and explanations of the business to be conducted, such as approval of share issues and option grants. There is no financial data or report content; rather, it is a formal notice and explanatory statement sent to shareholders to inform them and solicit votes for the meeting. This matches the definition of Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings. The document is lengthy (15,000 characters) and contains detailed meeting and voting information, not just a brief announcement, so it is not a Report Publication Announcement (RPA). Therefore, the correct classification is PSI.
2025-01-16 English
Change in substantial holding 6 pages 576.0KB
Regulatory Filings Classification · 90% confidence The document text provided is almost entirely composed of placeholders indicating omitted pictures and does not contain any readable text, financial data, regulatory references, or report titles. The length is 15,000 characters, which is substantial, but the content is not actual text but image placeholders. There is no indication of the document being an announcement, certification, or any specific report type. Given the lack of substantive content and the absence of any identifiable report or announcement, the document cannot be classified as a specific report type such as Annual Report, Interim Report, Earnings Release, or others. According to the rules, when a document does not neatly fit into any specific category due to lack of content or clarity, it should be classified as Regulatory Filings (RNS), which is the fallback category for miscellaneous filings.
2024-12-22 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.